Search results
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 1 day agoThe trial results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 3 days agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 17 hours ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Motley Fool via Yahoo Finance· 5 days agoAstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly...
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
Reuters via AOL· 5 days agoAmgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 7 hours agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 22 hours agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? | The Motley Fool
The Motley Fool· 5 days agoAstraZeneca (AZN -0.70%) is embarking on a fresh business plan that will see it grow significantly...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 4 days agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 4 days agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...